Jupiter Life Line Hospitals Shares List with 46% Gain on Strong IPO Subscription and Financial Performance
Jupiter Life Line Hospitals shares listed on the National Stock Exchange (NSE) on September 18, 2023, with a gain of 46.36% over the issue price of Rs 735. The stock touched an intraday high of Rs 1,108.95 and finally settled at Rs 1,075.75, with a volume of 1.28 crore equity shares.
The robust IPO subscription of 63.72 times during September 6-8, healthy financial performance in the past years, and the strong outlook for the healthcare sector boosted investor confidence.
The company has raised Rs 869 crore via public issue, including a fresh issue of Rs 542 crore, which will be utilized mainly for repaying debts worth Rs 510.4 crore and the remaining for general corporate purposes.
Jupiter Hospital is a well-established multi-specialty healthcare provider in the western region of India, and it is planning to expand its operations in the future. The company operates three hospitals in the Mumbai Metropolitan Area (MMR) and the western region of India (Thane, Pune, and Indore) with a total capacity of 1,194 beds as of March 2023. It has also started the construction of a fourth multi-specialty hospital in Dombivli, Maharashtra, with a capacity of over 500 beds.
- 22 Sep
Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits
Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.
- 22 Sep
Signature Global IPO Subscribed 11.88 Times on Final Day
The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.
- 22 Sep
Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding
Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.
- 22 Sep
Pharma company Valiant Laboratories to go public on September 27
Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.
- 21 Sep
Unihealth Consultancy makes tepid debut on NSE Emerge
Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.